Last Close
Mar 18  •  01:54PM ET
295.22
Dollar change
-0.53
Percentage change
-0.18
%
IndexS&P 500 P/E11.76 EPS (ttm)25.11 Insider Own0.28% Shs Outstand220.72M Perf Week1.87%
Market Cap65.16B Forward P/E10.13 EPS next Y29.15 Insider Trans-0.03% Shs Float220.09M Perf Month-14.37%
Enterprise Value- PEG2.32 EPS next Q10.74 Inst Own93.32% Short Float1.92% Perf Quarter-18.15%
Income5.66B P/S0.33 EPS this Y-14.63% Inst Trans1.49% Short Ratio2.22 Perf Half Y-4.77%
Sales199.12B P/B1.48 EPS next Y12.73% ROA4.75% Short Interest4.23M Perf YTD-15.78%
Book/sh198.81 P/C- EPS next 5Y4.36% ROE13.29% 52W High458.75 -35.65% Perf Year-32.33%
Cash/sh- P/FCF20.53 EPS past 3/5Y1.27% 6.99% ROIC7.53% 52W Low273.71 7.86% Perf 3Y-36.26%
Dividend Est.7.11 (2.41%) EV/EBITDA- Sales past 3/5Y8.34% 10.32% Gross Margin- Volatility2.72% 3.53% Perf 5Y-16.44%
Dividend TTM6.85 (2.32%) EV/Sales- EPS Y/Y TTM-2.29% Oper. Margin4.07% ATR (14)10.67 Perf 10Y106.91%
Dividend Ex-DateMar 10, 2026 Quick Ratio- Sales Y/Y TTM12.62% Profit Margin2.84% RSI (14)40.06 Recom2.04
Dividend Gr. 3/5Y10.14% 12.47% Current Ratio1.54 EPS Q/Q36.35% SMA20-3.03% Beta0.49 Target Price375.80
Payout27.13% Debt/Eq0.75 Sales Q/Q9.47% SMA50-11.69% Rel Volume0.44 Prev Close295.75
Employees97100 LT Debt/Eq0.71 EarningsJan 28 BMO SMA200-11.31% Avg Volume1.90M Price295.22
IPOOct 30, 2001 Option/ShortYes / Yes EPS/Sales Surpr.7.54% -1.07% Trades Volume584,742 Change-0.18%
Date Action Analyst Rating Change Price Target Change
Feb-03-26Downgrade RBC Capital Mkts Outperform → Sector Perform $358
Jan-08-26Upgrade Wolfe Research Peer Perform → Outperform $425
Dec-19-25Downgrade Deutsche Bank Buy → Hold $320
Oct-14-25Initiated Goldman Neutral
Jul-21-25Downgrade Argus Buy → Hold
Jul-18-25Downgrade Leerink Partners Outperform → Market Perform $310
Apr-15-25Downgrade Robert W. Baird Outperform → Neutral $529
Mar-17-25Upgrade Argus Hold → Buy $450
Jan-22-25Downgrade Stephens Overweight → Equal-Weight $520 → $440
Oct-18-24Downgrade Argus Buy → Hold
Mar-10-26 01:41PM
Mar-09-26 11:56AM
Mar-03-26 10:00AM
04:25AM
Mar-02-26 05:05PM
04:38PM Loading…
04:38PM
04:37PM
04:01PM
01:19PM
12:30PM
12:12PM
11:19AM
10:53AM
09:25AM
07:35AM
05:45AM Loading…
Feb-27-26 05:45AM
Feb-26-26 03:02PM
Feb-25-26 12:42PM
12:14PM
Feb-24-26 10:06AM
08:45AM
Feb-20-26 11:55AM
Feb-19-26 04:02PM
Feb-18-26 04:50PM
07:09AM
Feb-17-26 06:01PM
Feb-15-26 11:40PM
Feb-11-26 11:02PM
09:47AM
07:04AM
05:15PM Loading…
Feb-10-26 05:15PM
12:31PM
08:00AM
Feb-09-26 02:08PM
Feb-06-26 01:32PM
01:23PM
11:31AM
10:41AM
09:50AM
Feb-04-26 06:46AM
12:38AM
Feb-03-26 12:36PM
09:34AM
03:08AM
Feb-02-26 11:18AM
10:47AM
Jan-31-26 07:48AM
Jan-29-26 02:44PM
09:13AM
02:19AM
12:37AM
Jan-28-26 04:32PM
04:02PM
01:35PM
01:01PM
12:35PM
12:21PM
11:15AM
10:20AM
10:09AM
10:06AM
09:30AM
07:42AM
07:10AM
06:41AM
06:26AM
06:17AM
06:00AM
Jan-27-26 05:33PM
05:12PM
04:54PM
04:44PM
04:44PM
04:38PM
04:34PM
04:17PM
04:13PM
03:27PM
12:55PM
12:44PM
11:55AM
11:42AM
11:41AM
11:15AM
10:35AM
10:07AM
09:55AM
07:17AM
07:16AM
12:09AM
12:09AM
Jan-26-26 10:19PM
10:09PM
08:20AM
Jan-25-26 12:39PM
07:52AM
Jan-24-26 09:00AM
Jan-23-26 05:25PM
04:42PM
09:15AM
Elevance Health, Inc. operates as a health company, which engages in improving lives and communities, and making healthcare simpler. It operates through the following segments: Health Benefits, CarelonRx, Carelon Services, and Corporate and Other. The Health Benefits segment offers a comprehensive suite of health plans and services to different customers. The CarelonRx segment markets and offers pharmacy services to affiliated health plan customers, as well as to external customers. The Carelon Services segment integrates physical, behavioral, pharmacy, and social services with the aim of delivering whole health affordably by offering a broad array of healthcare related services. The Corporate & Other segment includes businesses that do not individually meet the quantitative threshold for an operating segment. The company was founded in 1944 and is headquartered in Indianapolis, IN.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Kendrick Charles Morgan JREVP & President, CommercialMar 06 '26Sale284.923,196910,60411,791Mar 09 04:45 PM
CHARLES MORGAN KENDRICKOfficerMar 06 '26Proposed Sale284.923,196910,593Mar 06 04:17 PM
COLLIS STEVEN HDirectorMar 05 '26Buy289.843,000869,5203,639Mar 06 08:03 AM
DeVore Susan D.DirectorAug 19 '25Buy312.151,200374,5803,502Aug 21 04:20 PM
BOUDREAUX GAILPresident and CEOJul 18 '25Buy286.948,5002,438,951151,020Jul 18 01:42 PM
Kaye MarkEVP & CFOApr 24 '25Sale424.824,5881,949,07418,977Apr 25 04:17 PM
Kaye MarkOfficerApr 24 '25Proposed Sale424.814,5881,949,051Apr 24 05:10 PM
Last Close
Mar 18  •  01:54PM ET
16.17
Dollar change
-0.54
Percentage change
-3.26
%
BLCO Bausch + Lomb Corp daily Stock Chart
Index- P/E- EPS (ttm)-1.02 Insider Own89.29% Shs Outstand354.21M Perf Week-7.63%
Market Cap5.73B Forward P/E15.33 EPS next Y1.05 Insider Trans0.02% Shs Float37.94M Perf Month-8.83%
Enterprise Value10.65B PEG0.40 EPS next Q0.06 Inst Own10.58% Short Float7.01% Perf Quarter-5.41%
Income-360.00M P/S1.12 EPS this Y51.76% Inst Trans-0.84% Short Ratio6.83 Perf Half Y8.49%
Sales5.10B P/B0.89 EPS next Y36.24% ROA-2.62% Short Interest2.66M Perf YTD-5.36%
Book/sh18.20 P/C14.43 EPS next 5Y38.29% ROE-5.57% 52W High18.92 -14.54% Perf Year4.43%
Cash/sh1.12 P/FCF- EPS past 3/5Y- - ROIC-3.10% 52W Low10.45 54.69% Perf 3Y1.79%
Dividend Est.- EV/EBITDA17.48 Sales past 3/5Y10.62% 8.38% Gross Margin54.75% Volatility2.90% 3.46% Perf 5Y-
Dividend TTM- EV/Sales2.09 EPS Y/Y TTM-12.96% Oper. Margin3.69% ATR (14)0.59 Perf 10Y-
Dividend Ex-Date- Quick Ratio1.04 Sales Y/Y TTM6.47% Profit Margin-7.06% RSI (14)37.37 Recom2.60
Dividend Gr. 3/5Y- - Current Ratio1.55 EPS Q/Q-1825.88% SMA20-7.76% Beta0.61 Target Price18.65
Payout- Debt/Eq0.81 Sales Q/Q9.77% SMA50-6.25% Rel Volume0.72 Prev Close16.71
Employees13000 LT Debt/Eq0.80 EarningsFeb 18 BMO SMA2005.20% Avg Volume389.34K Price16.17
IPOMay 06, 2022 Option/ShortYes / Yes EPS/Sales Surpr.-9.91% 1.42% Trades Volume193,236 Change-3.26%
Date Action Analyst Rating Change Price Target Change
Jan-05-26Downgrade Evercore ISI Outperform → In-line $18
Dec-11-25Upgrade Citigroup Neutral → Buy $20
Dec-02-25Upgrade Morgan Stanley Equal-Weight → Overweight $21
Oct-01-25Initiated Goldman Neutral $16
May-02-25Reiterated H.C. Wainwright Buy $20 → $15
Mar-28-25Downgrade Wells Fargo Overweight → Equal Weight $24 → $15
Dec-11-24Downgrade Citigroup Buy → Neutral $24 → $22
Dec-02-24Downgrade Morgan Stanley Overweight → Equal-Weight $19
Oct-15-24Upgrade Evercore ISI In-line → Outperform $19 → $25
Jul-10-24Initiated Raymond James Outperform $19
Mar-11-26 06:00AM
Mar-09-26 07:15AM
Feb-27-26 12:57PM
05:14AM
Feb-25-26 12:36AM
07:00AM Loading…
Feb-24-26 07:00AM
Feb-19-26 12:00PM
12:31AM
Feb-18-26 10:11PM
04:31PM
02:58PM
02:23PM
02:00PM
01:25PM
01:25PM
09:36AM Loading…
09:36AM
09:30AM
08:10AM
07:37AM
07:19AM
06:58AM
Feb-16-26 10:07PM
09:15AM
Feb-12-26 08:50AM
Feb-11-26 09:30AM
Feb-09-26 11:02PM
11:40AM
Jan-29-26 11:34PM
Jan-23-26 11:40AM
Jan-20-26 07:15AM
07:00AM Loading…
Jan-05-26 07:00AM
Jan-02-26 04:30PM
Dec-23-25 07:30AM
Dec-17-25 04:30PM
Dec-12-25 04:48PM
Dec-11-25 11:41AM
Dec-04-25 10:09PM
Dec-02-25 11:10AM
Nov-18-25 04:30PM
Nov-13-25 02:57PM
08:55AM
08:41AM
Nov-10-25 06:59AM
04:28AM
Nov-05-25 12:35AM
Nov-03-25 04:30PM
Oct-30-25 01:34AM
Oct-29-25 03:47PM
09:30AM
08:05AM
07:23AM
07:06AM
06:58AM
Oct-28-25 09:26AM
Oct-27-25 11:12PM
Oct-20-25 06:44PM
11:36AM
09:34AM
07:41AM
07:25AM
Oct-19-25 08:00PM
Oct-17-25 12:24PM
Oct-10-25 06:44PM
Oct-02-25 11:40AM
Oct-01-25 11:01AM
Sep-25-25 01:06PM
Sep-11-25 07:00AM
Sep-09-25 07:00AM
Sep-08-25 06:56PM
04:30PM
07:00AM
Sep-05-25 12:41AM
Aug-22-25 02:25PM
Aug-20-25 11:31PM
Aug-18-25 05:48PM
05:01PM
Aug-14-25 07:15AM
Aug-12-25 11:55PM
11:48PM
Aug-07-25 12:38AM
Jul-30-25 03:05PM
12:16PM
09:30AM
08:10AM
07:34AM
07:04AM
06:57AM
05:38AM
Jul-29-25 09:27AM
07:00AM
Jul-28-25 11:09PM
Jul-24-25 05:04AM
Jul-23-25 10:00AM
Jul-22-25 08:45AM
Jul-21-25 09:13AM
Jul-20-25 11:31PM
Jul-01-25 07:00AM
Jun-30-25 06:58AM
Jun-26-25 04:30PM
Jun-25-25 07:42AM
Bausch + Lomb Corp. develops, manufactures, and markets eye health products. It offers over-the-counter supplements, eye care products, ophthalmic pharmaceuticals, contact lenses, lens care, ophthalmic surgical devices, and instruments. The company operates its business through three segments: Vision Care/Consumer Health Care, Ophthalmic Pharmaceuticals and Surgical. The Vision Care/Consumer Health Care segment includes both contact lens and consumer eye care businesses. The Ophthalmic Pharmaceuticals segment consists of a broad line of proprietary pharmaceutical products for post-operative treatments and treatments for a number of eye conditions, such as glaucoma, eye inflammation, ocular hypertension, dry eyes and retinal diseases. The Surgical segment consists of medical device equipment, consumables and instrumental tools and technologies for the treatment of corneal, cataracts, and vitreous and retinal eye conditions, and includes IOLs and delivery systems, phacoemulsification equipment and other surgical instruments and devices necessary for cataract surgery. Bausch + Lomb was founded by John Jacob Bausch and Henry Lomb in 1853 and is headquartered in Vaughan, Canada.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Bailey A Robert DEVP & Chief Legal OfficerMar 06 '26Buy17.1514,600250,332231,890Mar 10 05:23 PM
Eldessouky SamEVP and CFOMar 06 '26Buy17.134,00068,520403,130Mar 10 04:34 PM
SAUNDERS BRENT LCEO and Chairman of the BoardMar 06 '26Buy17.1414,700251,958966,575Mar 10 04:32 PM
Ross Thomas W. Sr.DirectorMar 03 '26Buy17.684,50079,55664,891Mar 04 04:18 PM
Alfonso EduardoDirectorMar 02 '26Buy17.904,30076,9709,555Mar 03 04:26 PM
VON ESCHENBACH ANDREW C.DirectorFeb 27 '26Buy18.304,36479,88366,450Mar 03 04:24 PM
COLLIS STEVEN HDirectorFeb 23 '26Buy17.8115,000267,15020,255Feb 24 04:23 PM
ROBERTSON RUSSEL CDirectorFeb 20 '26Buy17.904,40078,76072,407Feb 24 04:16 PM
Ling KarenDirectorFeb 19 '26Buy17.744,00070,96841,676Feb 23 04:20 PM
SAUNDERS BRENT LCEO and Chairman of the BoardMay 22 '25Buy11.2822,000248,072719,156May 27 08:16 AM
VON ESCHENBACH ANDREW C.DirectorMay 02 '25Buy11.761,69519,92541,748May 06 04:30 PM
Last Close
Mar 18  •  01:54PM ET
323.41
Dollar change
-11.30
Percentage change
-3.38
%
COR Cencora Inc daily Stock Chart
IndexS&P 500 P/E38.90 EPS (ttm)8.31 Insider Own0.40% Shs Outstand194.52M Perf Week-7.68%
Market Cap62.91B Forward P/E16.50 EPS next Y19.60 Insider Trans-8.56% Shs Float193.76M Perf Month-10.16%
Enterprise Value69.21B PEG1.53 EPS next Q4.87 Inst Own96.31% Short Float2.45% Perf Quarter-7.68%
Income1.63B P/S0.19 EPS this Y10.16% Inst Trans1.03% Short Ratio4.01 Perf Half Y11.52%
Sales325.78B P/B32.97 EPS next Y11.19% ROA2.20% Short Interest4.75M Perf YTD-4.25%
Book/sh9.81 P/C34.78 EPS next 5Y10.79% ROE152.25% 52W High377.54 -14.34% Perf Year22.44%
Cash/sh9.30 P/FCF17.44 EPS past 3/5Y-0.34% - ROIC17.13% 52W Low260.23 24.28% Perf 3Y112.74%
Dividend Est.2.40 (0.74%) EV/EBITDA14.12 Sales past 3/5Y10.43% 11.09% Gross Margin3.28% Volatility2.57% 2.15% Perf 5Y179.69%
Dividend TTM2.30 (0.71%) EV/Sales0.21 EPS Y/Y TTM18.24% Oper. Margin1.18% ATR (14)9.86 Perf 10Y269.69%
Dividend Ex-DateFeb 13, 2026 Quick Ratio0.51 Sales Y/Y TTM7.45% Profit Margin0.50% RSI (14)27.23 Recom1.61
Dividend Gr. 3/5Y6.14% 5.79% Current Ratio0.92 EPS Q/Q14.47% SMA20-9.58% Beta0.68 Target Price414.15
Payout27.63% Debt/Eq4.15 Sales Q/Q5.45% SMA50-8.79% Rel Volume0.80 Prev Close334.71
Employees51000 LT Debt/Eq3.97 EarningsFeb 04 BMO SMA200-0.34% Avg Volume1.19M Price323.41
IPOApr 04, 1995 Option/ShortYes / Yes EPS/Sales Surpr.0.77% -0.15% Trades Volume659,492 Change-3.38%
Date Action Analyst Rating Change Price Target Change
Jan-29-26Upgrade Morgan Stanley Equal-Weight → Overweight $400
Jan-22-26Upgrade Jefferies Hold → Buy $440
Dec-09-25Initiated Barclays Overweight $400
Jun-03-25Upgrade Wells Fargo Equal Weight → Overweight $337
Dec-04-24Resumed Mizuho Outperform $280
Sep-18-24Downgrade BofA Securities Buy → Neutral $275 → $245
Feb-26-24Initiated Leerink Partners Outperform $261
Jan-03-24Initiated Barclays Overweight $242
Dec-14-23Initiated Wells Fargo Equal Weight $213
Mar-31-23Initiated Citigroup Buy $185
Mar-17-26 04:36PM
11:17AM
10:15AM
08:30AM
05:32AM
04:41PM Loading…
Mar-13-26 04:41PM
Mar-06-26 07:12PM
11:30AM
07:26AM
Mar-02-26 04:31AM
Feb-26-26 07:12PM
Feb-19-26 07:56AM
Feb-18-26 07:00AM
Feb-17-26 08:52AM
Feb-13-26 04:15PM
03:51PM Loading…
03:51PM
Feb-11-26 11:37PM
12:36AM
Feb-10-26 05:15PM
07:31AM
Feb-06-26 09:28AM
Feb-05-26 03:31PM
01:58PM
12:48PM
10:35AM
01:13AM
12:34AM
Feb-04-26 11:42PM
04:05PM
01:44PM
11:59AM Loading…
11:59AM
11:32AM
11:12AM
10:04AM
10:03AM
09:30AM
07:40AM
06:47AM
06:38AM
06:30AM
Feb-02-26 10:06PM
Feb-01-26 07:47AM
Jan-31-26 09:36AM
Jan-30-26 09:15AM
Jan-29-26 09:35AM
08:33AM
Jan-27-26 08:09PM
Jan-26-26 01:27PM
Jan-25-26 04:46AM
Jan-22-26 07:30AM
Jan-12-26 07:51AM
Jan-09-26 09:06AM
Jan-08-26 08:40PM
09:40AM
07:57AM
Jan-07-26 09:45AM
Jan-06-26 04:30PM
Jan-05-26 01:44PM
Dec-30-25 07:33AM
Dec-29-25 10:17AM
08:52AM
Dec-26-25 07:18AM
Dec-24-25 10:36PM
09:11AM
Dec-23-25 02:09PM
09:35AM
Dec-22-25 10:40AM
Dec-19-25 02:14PM
11:05AM
Dec-18-25 09:40AM
Dec-17-25 09:45AM
Dec-16-25 03:52AM
Dec-15-25 08:01PM
02:50PM
09:06AM
07:00AM
Dec-10-25 08:59AM
Dec-09-25 09:40AM
Dec-05-25 11:30AM
Dec-03-25 03:26PM
02:59PM
03:35AM
Dec-02-25 12:00PM
09:40AM
Dec-01-25 09:45AM
09:20AM
Nov-28-25 07:08AM
Nov-26-25 09:09AM
Nov-25-25 09:50AM
Nov-24-25 09:15AM
Nov-21-25 09:40AM
Nov-18-25 09:15AM
Nov-17-25 08:40AM
Nov-14-25 09:45AM
Nov-13-25 09:40AM
Nov-12-25 12:36AM
Nov-11-25 04:51AM
Nov-07-25 09:50AM
Nov-06-25 04:45PM
06:21AM
Cencora, Inc. is a pharmaceutical sourcing and distribution services company. It operates through the United States (U.S.) Healthcare Solutions and International Healthcare Solutions segments. The U.S. Healthcare Solutions segment is involved in the offering of brand-name, specialty brand-name and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to a wide variety of healthcare providers. The International Healthcare Solutions segment includes businesses that focus on international pharmaceutical wholesale and related service operations, and global commercialization services. The company was founded by Emil P. Martini in 1947 and is headquartered in Conshohocken, PA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Battaglia SilvanaExecutive Vice PresidentMar 11 '26Option Exercise0.008,415027,239Mar 13 04:17 PM
Campbell Elizabeth SExecutive Vice PresidentMar 11 '26Option Exercise0.0012,623036,548Mar 13 04:16 PM
Cleary James FChief Financial OfficerMar 11 '26Option Exercise0.0012,6230165,766Mar 13 04:14 PM
Mauch Robert P.President & CEOFeb 20 '26Option Exercise86.093,762323,87169,155Feb 24 04:04 PM
Mauch Robert P.President & CEOFeb 20 '26Sale358.943,7621,350,33265,393Feb 24 04:04 PM
Mauch Robert P.President & CEOFeb 18 '26Sale359.461,333479,16065,393Feb 20 04:00 PM
Mauch Robert P.OfficerFeb 20 '26Proposed Sale358.943,7621,350,332Feb 20 12:27 PM
Mauch Robert P.OfficerFeb 18 '26Proposed Sale359.461,333479,160Feb 18 11:03 AM
Mauch Robert P.President & CEOJan 20 '26Option Exercise86.093,763323,95771,822Jan 22 04:43 PM
Mauch Robert P.President & CEOJan 20 '26Sale354.735,0961,807,70466,726Jan 22 04:43 PM
Mauch Robert P.OfficerJan 20 '26Proposed Sale354.735,0961,807,704Jan 20 11:14 AM
Battaglia SilvanaExecutive Vice PresidentDec 19 '25Sale345.001,677578,56518,796Dec 22 04:15 PM
Campbell Elizabeth SExecutive Vice PresidentDec 19 '25Sale342.103,3511,146,37723,891Dec 22 04:15 PM
Mauch Robert P.President & CEODec 18 '25Option Exercise86.093,763323,95773,155Dec 22 04:14 PM
Mauch Robert P.President & CEODec 18 '25Sale343.455,0961,750,22168,059Dec 22 04:14 PM
Campbell Elizabeth SOfficerDec 19 '25Proposed Sale342.103,3511,146,377Dec 19 04:15 PM
Krikorian LazarusSVP & Chief Accounting OfficerDec 17 '25Sale343.244,0311,383,58017,154Dec 19 04:04 PM
Cleary James FChief Financial OfficerDec 17 '25Option Exercise86.0945,1543,887,308180,095Dec 19 04:03 PM
Battaglia SilvanaOfficerDec 19 '25Proposed Sale345.001,677578,565Dec 19 11:03 AM
Mauch Robert P.OfficerDec 18 '25Proposed Sale343.455,0961,750,221Dec 18 09:48 AM
Krikorian LazarusOfficerDec 17 '25Proposed Sale343.244,0311,383,580Dec 17 03:55 PM
Mauch Robert P.President & CEONov 18 '25Option Exercise86.093,763323,95770,842Nov 19 05:09 PM
Mauch Robert P.President & CEONov 18 '25Sale366.645,0961,868,39765,746Nov 19 05:09 PM
Mauch Robert P.OfficerNov 18 '25Proposed Sale366.645,0961,868,397Nov 18 11:43 AM
COLLIS STEVEN HFormer Officer & DirectorNov 18 '25Proposed Sale366.6431,34911,493,797Nov 18 10:40 AM
COLLIS STEVEN HFormer Officer & DirectorNov 06 '25Proposed Sale355.2550,00017,762,554Nov 06 04:16 PM
Verma PawanEVP, Chief Data & Info OfficerOct 31 '25Option Exercise337.818,5372,883,8848,551Nov 04 04:15 PM
Mauch Robert P.President & CEOOct 20 '25Option Exercise86.093,763323,95743,037Oct 21 04:33 PM
Mauch Robert P.President & CEOOct 20 '25Sale326.805,0971,665,70037,940Oct 21 04:33 PM
COLLIS STEVEN HFormer Officer & DirectorOct 21 '25Proposed Sale326.9931,35010,251,105Oct 21 04:16 PM
Mauch Robert P.OfficerOct 20 '25Proposed Sale326.805,0971,665,700Oct 20 09:36 AM
Campbell Elizabeth SExecutive Vice PresidentOct 01 '25Sale313.281,886590,84612,824Oct 03 04:01 PM
Campbell Elizabeth SOfficerOct 01 '25Proposed Sale313.281,886590,846Oct 01 10:36 AM
Mauch Robert P.President & CEOSep 18 '25Option Exercise86.093,763323,95744,371Sep 22 04:16 PM
Mauch Robert P.President & CEOSep 18 '25Sale290.005,0971,478,13039,274Sep 22 04:16 PM
COLLIS STEVEN HExecutive ChairmanSep 16 '25Option Exercise86.0929,3502,526,742337,263Sep 18 03:56 PM
COLLIS STEVEN HExecutive ChairmanSep 16 '25Sale289.8631,3509,087,142305,913Sep 18 03:56 PM
Mauch Robert P.OfficerSep 18 '25Proposed Sale290.005,0971,478,130Sep 18 11:54 AM
COLLIS STEVEN HDirectorSep 16 '25Proposed Sale291.5531,3509,140,092Sep 16 10:27 AM
COLLIS STEVEN HExecutive ChairmanAug 19 '25Option Exercise86.0912,5791,082,926322,492Aug 20 04:08 PM
COLLIS STEVEN HExecutive ChairmanAug 19 '25Sale289.9814,5794,227,618307,913Aug 20 04:08 PM
Mauch Robert P.President & CEOAug 18 '25Option Exercise86.093,225277,64045,576Aug 20 04:06 PM
Mauch Robert P.President & CEOAug 18 '25Sale293.534,9681,458,25740,608Aug 20 04:06 PM
COLLIS STEVEN HDirectorAug 19 '25Proposed Sale289.9814,5794,227,618Aug 19 09:51 AM
Mauch Robert P.OfficerAug 18 '25Proposed Sale293.534,9681,458,257Aug 18 11:06 AM
COLLIS STEVEN HExecutive ChairmanJul 22 '25Option Exercise86.0912,5781,082,840324,491Jul 23 04:30 PM
COLLIS STEVEN HExecutive ChairmanJul 22 '25Sale292.6714,5784,266,543309,913Jul 23 04:30 PM
Mauch Robert P.President & CEOJul 18 '25Option Exercise86.093,225277,64047,319Jul 22 04:23 PM
Mauch Robert P.President & CEOJul 18 '25Sale294.114,9681,461,13842,351Jul 22 04:23 PM
COLLIS STEVEN HDirectorJul 22 '25Proposed Sale292.6714,5784,266,543Jul 22 09:47 AM
Mauch Robert P.OfficerJul 18 '25Proposed Sale294.114,9681,461,138Jul 18 11:44 AM
COLLIS STEVEN HExecutive ChairmanJun 24 '25Option Exercise86.0912,5791,082,926326,492Jun 25 04:03 PM
COLLIS STEVEN HExecutive ChairmanJun 24 '25Sale292.6214,5794,266,107311,913Jun 25 04:03 PM
COLLIS STEVEN HDirectorJun 24 '25Proposed Sale292.6214,5794,266,107Jun 24 10:21 AM
Battaglia SilvanaExecutive Vice PresidentJun 18 '25Sale297.404,0771,212,52011,297Jun 20 04:06 PM
Mauch Robert P.President & CEOJun 18 '25Option Exercise86.093,225277,64049,063Jun 20 04:04 PM
Mauch Robert P.President & CEOJun 18 '25Sale295.304,9691,467,34644,094Jun 20 04:04 PM
Lon GreenbergBoard of directorsJun 18 '25Proposed Sale293.201,000293,200Jun 18 04:40 PM
Battaglia SilvanaOfficerJun 18 '25Proposed Sale297.414,0771,212,520Jun 18 12:58 PM
Mauch Robert P.OfficerJun 18 '25Proposed Sale295.304,9691,467,346Jun 18 09:50 AM
Krikorian LazarusSVP & Chief Accounting OfficerMay 29 '25Sale288.963,000866,88117,154Jun 02 04:08 PM
Krikorian LazarusOfficerMay 29 '25Proposed Sale288.963,000866,881May 29 11:37 AM
Mauch Robert P.President & CEOMay 19 '25Option Exercise86.093,225277,64050,807May 21 04:04 PM
Mauch Robert P.President & CEOMay 19 '25Sale291.434,9691,448,11645,838May 21 04:04 PM
COLLIS STEVEN HExecutive ChairmanMay 20 '25Option Exercise86.0912,5781,082,840328,491May 21 04:00 PM
COLLIS STEVEN HExecutive ChairmanMay 20 '25Sale293.8414,5784,283,600313,913May 21 04:00 PM
COLLIS STEVEN HDirectorMay 20 '25Proposed Sale293.8414,5784,283,600May 20 09:45 AM
Hopfield JessicaMember of immediate family of May 19 '25Proposed Sale293.2412,1853,573,163May 19 02:29 PM
Mauch Robert P.OfficerMay 19 '25Proposed Sale291.434,9691,448,116May 19 09:51 AM
GREENBERG LON RDirectorMay 14 '25Sale279.053,000837,15017,851May 16 04:23 PM
GREENBERG LON RDirectorMay 14 '25Proposed Sale279.053,000837,150May 14 03:53 PM
COLLIS STEVEN HExecutive ChairmanApr 22 '25Option Exercise86.0912,5791,082,926330,492Apr 23 04:24 PM
COLLIS STEVEN HExecutive ChairmanApr 22 '25Sale281.8114,5794,108,508315,913Apr 23 04:24 PM
Mauch Robert P.President & CEOApr 21 '25Option Exercise86.093,225277,64052,551Apr 22 04:06 PM
Mauch Robert P.President & CEOApr 21 '25Sale289.334,9691,437,68147,582Apr 22 04:06 PM
COLLIS STEVEN HDirectorApr 22 '25Proposed Sale281.8114,5794,108,508Apr 22 09:42 AM
Mauch Robert P.OfficerApr 21 '25Proposed Sale289.334,9691,437,681Apr 21 09:48 AM
COLLIS STEVEN HExecutive ChairmanMar 25 '25Option Exercise86.0912,5781,082,840332,491Mar 26 04:40 PM
COLLIS STEVEN HExecutive ChairmanMar 25 '25Sale269.5114,5783,928,917317,913Mar 26 04:40 PM
Campbell Elizabeth SExecutive Vice PresidentMar 24 '25Sale268.284,1271,107,19214,665Mar 26 04:38 PM
COLLIS STEVEN HDirectorMar 25 '25Proposed Sale269.5114,5783,928,917Mar 25 10:16 AM
Campbell Elizabeth SOfficerMar 24 '25Proposed Sale268.284,1271,107,192Mar 24 10:53 AM